The use of biologic and targeted therapies for children with juvenile idiopathic arthritis (JIA) surpassed more typical therapies in recent years, according to researchers.

Daniel Horton Rutgers Center for Pharmacoepidemiology and Treatment Science Researchers used data from privately insured ...

The use of biologic and targeted therapies for children with juvenile idiopathic arthritis (JIA) surpassed more typical ...